Vulval cancer survival statistics

Coronavirus (COVID-19)

We have created a central resources hub for Health Professionals which hosts all of our CRUK resources and further materials to help with managing the pandemic. We are updating the information as guidance changes. There is also a page specifically for patients on our about cancer hub.

Health Professional COVID-19 and Cancer Hub


Survive vulval cancer for 10 or more years, 2009-2011, England


Age that vaginal and vulva cancers survival is highest, 2009-2013, England


86.1% of females survive vulval cancer for at least one year, this falls to 67.1% surviving for five years or more, as shown by age-standardised net survival for patients diagnosed with vulval cancer during 2013-2017 in England.[1]

Vulval Cancer Age-Standardised One- and Five-Year Net Survival, Adults (Aged 15-99), England, 2009-2013

The bar chart shows one- and five-year net survival and predicted ten-year net survival, with 95% confidence intervals. Open a glossary item


Ten-year survival estimates are not available for this cancer.



  1. Office for National Statistics, Cancer survival by stage at diagnosis for England, 2019.

About this data

Data is for England, 2013 - 2017, ICD-10 C67.

Survival statistics give an overall picture of survival and the survival time experienced by an individual patient may be much higher or lower, depending on specific patient and tumour characteristics.

Last reviewed:

Five-year survival for vaginal or vulval cancer is highest in the youngest women and decreases with increasing age. Five-year net survival in women ranges from 82% in 15-49 year olds to 55% in 70-89 year-olds for patients diagnosed with vaginal or vulval cancer in England during 2009-2013.[1]

Vaginal or Vulval Cancer (C51, C52), Five-Year Net Survival by Age, England, 2009-2013


  1. Muller P, Belot A, Morris M, Rachet B, Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine. Net survival and the probability of cancer death from rare cancers. Available from Accessed July 2016.

About this data

Data is for: England, 2009-2013, ICD-10 C51, C52

Last reviewed:

Survival for vulval cancer is strongly related to stage of the disease at diagnosis.

One-year net survival by stage

One-year net survival for vulval cancer is highest for patients diagnosed at Stage 1, and lowest for those diagnosed at Stage 4, as 2013-2017 data for England show.[1] 96% of patients diagnosed at Stage 1 survived their disease for at least one year, compared to 43% of patients diagnosed at Stage 4.[1]

One year net survival for unknown or missing stage is 81%. Lack of staging information may in some cases reflect advanced stage at diagnosis as very unwell patients may not undergo staging tests if the invasiveness of the testing outweighs the potential benefit of obtaining stage information. Incomplete staging assessment may also be associated with socio-demographic and clinical characteristics of the patient [2]. Stage completeness for vulval cancer was 75% in 2013-2017 [1].

Vulva cancer one-year net survival by stage, with incidence by stage (all data: adults diagnosed 2013-2017, followed up to 2018)


  1. Office for National Statistics, Cancer survival by stage at diagnosis for England, 2019.
  2. Girolamo, C. et al, Characteristics of patients with missing information on stage: a population-based study of patients diagnosed with a colon, lung or breast cancer in England in 2013, BMC Cancer (2018) 18:492

About this data

Data is for: England, 2013 - 2017, ICD-10 C51.

Survival statistics give an overall picture of survival but the survival time experienced by an individual patient may be much higher or lower, depending on specific patient and tumour characteristics.

Last reviewed:

Five-year relative survival for vaginal and vulval cancer in women in England (60%), Scotland (61%) and Northern Ireland (60%) are above the average for Europe (57%). Wales (57%) is similar to the European average.[1] Across the European countries for which data is available, five-year relative survival in women ranges from 41% (Slovakia) to 65% (The Netherlands).[1

Vaginal and Vulval Cancer (C51, C52.9, C57.8, C57.9), Age-Standardised Five-Year Relative Survival, Females (Aged 15+), European Countries, 2000-2007

Data consists of both observed and predicted 5-year relative survival. Where sufficient follow-up was not available for recently diagnosed patients the period approach was used to predict 5-year cohort survival.

Possible explanations for persistent international differences in survival include differences in cancer biology, use of diagnostic tests and screening, stage at diagnosis, access to high-quality care, and data collection practices.[1]


  1. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 - a population-based study. Lancet Oncol 2014;15:23-34

About this data

Data is for: 29 European countries, patients diagnosed in 2000-2007 and followed up to 2008, vaginal and vulval cancer (C51, C52.9, C57.8, C57.9).

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.


You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

We’re now on twitter.
Join the conversation and follow @CRUKHCPs for news, updates and opinion.



We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.